@article{fdi:010046135,
  title = {{C}omparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated {P}lasmodium falciparum malaria in {B}enin : a randomized effectiveness noninferiority trial},
  author = {{F}aucher, {J}.{F}. and {A}ubouy, {A}gn{\`e}s and {A}deothy, {A}dicat and {C}ottrell, {G}illes and {D}oritchamou, {J}ustin and {G}ourmel, {B}. and {H}ouze, {P}. and {K}ossou, {H}. and {A}medome, {H}. and {M}assougbodji, {A}. and {C}ot, {M}ichel and {D}eloron, {P}hilippe},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground. {W}e compared sulfadoxine-pyrimethamine ({SP}) with unsupervised artemether-lumefantrine ({AL}) and unsupervised amodiaquine-artesunate ({ASAQ}) fixed-dose formulation for the treatment of uncomplicated malaria in children in {B}enin. {M}ethods. {T}his open-label, noninferiority comparative trial included children aged 6-60 months. {T}he follow-up period was 6 weeks, and the primary objective was a comparison of polymerase chain reaction ({PCR})-adjusted effectiveness rates at day 28. {R}esults. {T}he study included 240 children (48 received {SP}, and 96 each received {AL} and {ASAQ}). {T}he intention-to-treat analysis showed effectiveness rates on day 28 of 20.8%, 78.1%, and 70.5% for {SP}, {AL}, and {ASAQ}, respectively. {A}fter adjustment for {PCR} results, these rates were 27.1%, 83.3%, and 87.4%, respectively. {T}he per-protocol analysis (217 patients) showed effectiveness rates on day 28 of 21.7%, 88.0%, and 76.1% for {SP}, {AL}, and {ASAQ}, respectively. {A}fter adjustment for {PCR} results, these rates were 28.3%, 94.0%, and 93.2%, respectively. {SP} was less effective than the other drugs in the {PCR}-adjusted analysis, whereas {AL} and {ASAQ} were equally effective. {T}he rate of new infection was higher among children treated with {ASAQ} than among those treated with {AL}. {C}onclusions. {T}his was the first trial, to our knowledge, to compare unsupervised {AL} with unsupervised {ASAQ} fixed-dose formulation; both treatments provided high {PCR}-adjusted day 28 effectiveness rates. {E}fficacy rates for {SP} were surprisingly low.},
  keywords = {},
  booktitle = {},
  journal = {{J}ournal of {I}nfectious {D}iseases},
  volume = {200},
  numero = {1},
  pages = {57--65},
  ISSN = {0022-1899},
  year = {2009},
  DOI = {10.1086/599378},
  URL = {https://www.documentation.ird.fr/hor/fdi:010046135},
}